Promus Diagnostics, LLC

Promus Diagnostics, LLC was paid $277K by Medicaid between Jun 2020 and Jun 2023, across 23 billing codes. Its largest line is U0003, Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r — 85% of everything it billed.

Compared with peers

Next to other Clinical Medical Laboratory providers in Texas

Rank by total paid#114 of 436

Median peer was paid$17K

This provider vs. median16×

Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.

Box 24A · Dates of service

Paid by month

Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider

By year, as a table

Year	Claims	Paid
2020	3,889	$3K
2021	7,771	$212K
2022	8,538	$61K
2023	3,347	$1K

Box 24 · Service lines

What it billed for

Code	Service	Share	Claims	Bene. records	Paid
U0003	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r	85%	5,055	1,932	$234K
U0005	Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2	12%	4,272	1,680	$34K
87798	Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism	2.0%	1,596	1,061	$6K
87150		<1%	794	597	$656.51
G2023	Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source	<1%	1,189	499	$564.24
87801	Infectious agent detection by nucleic acid; amplified probe, multiple organisms	<1%	803	598	$541.46
87481		<1%	1,547	1,059	$300.77
87500		<1%	1,578	1,053	$173.99
87641		<1%	1,538	1,049	$142.88
87653		<1%	1,557	1,061	$142.88
87640		<1%	1,564	1,062	$111.77
87651	Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe	<1%	560	428	$90.23

11 more codes

87556		<1%	381	$66.52
87511		<1%	249	$31.11
87491	Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe	<1%	205	$28.01
87661	Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe	<1%	206	$28.01
87591	Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe	<1%	207	$28.01
87811	Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19)	0%	106	$0.00
P9604	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge	0%	16	$0.00
86409		0%	12	$0.00
G0480	Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed	0%	16	$0.00
87426	Infectious agent antigen detection, SARS-CoV-2 (COVID-19)	0%	77	$0.00
P9603	Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled	0%	17	$0.00

Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.

From NPPES

Who's on the registration

Authorized officialSANSONE, VICTOR (OWNER)